Antiangiogenic agents combined with systemic chemotherapy in refractory osteosarcoma
Mené sur des patients âgés de 2 à 25 ans et atteints d'un ostéosarcome réfractaire ou récidivant, cet essai de phase I/II évalue la dose maximale tolérée du lenvatinib en combinaison avec l'étoposide et l'ifosfamide, puis l'efficacité, du point de vue de la survie sans progression à 4 mois, de cette combinaison
In The Lancet Oncology, Nathalie Gaspar and colleagues 1 report safety and activity data from the ongoing phase 1/2 ITCC-050 trial (NCT02432274), in which patients with refractory or relapsed osteosarcoma were given lenvatinib with etoposide plus ifosfamide. The authors should be congratulated for the study design and combining systemic cytotoxic chemotherapy with a tyrosine kinase inhibitor. This study will have an impact on future trials in patients with advanced pretreated osteosarcoma, which constitutes a population with an unmet need in clinical oncology. Notably, Gaspar and colleagues report a median progression-free survival of 8·7 months (95% CI 4·5–12·0) and progression-free survival at 4 months of 51% (34–69) for patients receiving lenvatinib with etoposide plus ifosfamide.
The Lancet Oncology , commentaire, 2020